Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Celldex Therapeutics, Inc.
Pfizer and Celldex Therapeutics Present Update on CDX-110 PF-04948568 Phase 2 Brain Cancer Studies at 45th Annual ASCO Meeting
June 17th, 2009
Pfizer (NYSE: PFE) and Celldex Therapeutics (NASDAQ: CLDX) announced the presentation of updated data from two clinical trials of CDX-110 in newly-diagnosed glioblastoma multiforme (GBM) at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO). CDX-110, an investigational immunotherapeutic vaccine that targets the tumor-specific molecule, epidermal growth factor receptor variant III (EGFRvIII), was developed by Celldex Therapeutics and is now partnered with Pfizer. “Data from the 40 evaluable patients in ACTIVATE and ACT II continue to suggest that vaccination with CDX-110 may be able to improve time to tumor recurrence and overall survival when...
Source: Vaccine Weekly (2009-06-17)
|
